Table 2. Candidate miRNAs selected in discovery phase and their results in validation phase.

	Discovery phase			Validation phase				Pooled analysis
	Mean Cq	FC*	P value	Mean Cq	FC*	FC†	P value	FC‡	P value
miR-103a-3p	28.0	0.43	0.0011	25.9	0.86	1.03	0.69	0.70	0.013
miR-107	29.5	0.68	0.0095	31.1	0.99	1.37	0.45	0.94	0.65
miR-1260a	32.8	1.57	0.021	31.2	0.73	1.47	0.11	1.21	0.20
miR-141-3p	36.3	2.73	0.044	35.3	1.05	1.52	0.58	1.70	0.071
miR-146b-5p	34.8	0.61	0.036	32.6	1.54	1.80	0.025	1.13	0.42
miR-194-5p	34.2	1.86	0.014	30.4	1.39	2.77	0.0025	1.92	0.00018
miR-19a-3p	27.7	0.68	0.020	25.1	0.82	0.86	0.47	0.77	0.013
miR-200a-3p	37.4	12.47	7.5E-06	36.4	1.22	2.37	0.10	3.69	7.1E-05
miR-200c-3p	35.4	2.48	0.05	34.5	1.57	0.79	0.18	1.52	0.108
miR-205-5p	36.4	7.04	0.0036	36.3	2.81	4.23	0.0071	4.55	8.5E-05
miR-21-5p	25.6	1.55	0.018	23.7	1.45	2.59	5.9E-07	1.78	5.2E-07
miR-221-3p	28.5	0.67	0.049	27.1	0.87	0.67	0.19	0.72	0.014
miR-301a-3p	32.8	0.68	0.043	30.5	1.01	1.33	0.53	0.94	0.69
miR-30b-5p	30.3	0.67	0.023	28.1	0.81	0.92	0.53	0.78	0.026
miR-320a	29.2	1.44	0.05	26.1	0.76	0.84	0.35	1.01	0.96
miR-375	34.1	2.21	0.05	33.9	3.15	3.40	0.0038	2.81	0.00014
miR-376c-3p	33.9	0.41	0.027	31.5	0.38	0.36	0.024	0.38	0.00051
miR-382-5p	34.7	0.27	0.0020	33.2	0.37	0.33	0.026	0.32	7.6E-05
miR-411-5p	38.0	0.49	0.15	35.6	0.36	0.46	0.038	0.44	0.006
miR-424-5p	34.7	1.89	0.027	29.4	0.57	0.59	0.015	0.88	0.11

Note: quantitation cycle (Cq); fold change (FC) = 2^ΔCq ; significant, consistent validated results are in bold

^*FC: fold change comparing samples at recurrence for patients who had recurrent diseases vs. samples at diagnosis for patients without recurrence

^†FC: fold change comparing samples at diagnosis for patients who had recurrence vs. samples at diagnosis for patients without recurrence

^‡FC: fold change comparing samples from patients with recurrence vs. patients without recurrence